Case Report: Psoriasiform Eczema with Immune-Mediated Comorbidities Treated with Upadacitinib

This case report discusses the use of upadacitinib, a selective JAK-1 inhibitor, in treating psoriasiform eczema and associated immune-mediated comorbidities in 5 male patients. The treatment was effective for psoriasiform eczema, with rapid improvement in all cases. Upadacitinib also showed good effectiveness for alopecia areata, partial improvement for vitiligo, complete remission for ulcerative colitis, and slight improvement for hidradenitis suppurativa. No adverse events were reported, suggesting upadacitinib's potential as a therapeutic option for multiple immune-mediated diseases. Further studies are recommended to assess its efficacy in conditions like alopecia areata, vitiligo, and hidradenitis suppurativa.